These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33923537)

  • 1. Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients.
    Gedefaw L; Ullah S; Leung PHM; Cai Y; Yip SP; Huang CL
    Cells; 2021 Apr; 10(4):. PubMed ID: 33923537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice.
    Zeng J; Xie X; Feng XL; Xu L; Han JB; Yu D; Zou QC; Liu Q; Li X; Ma G; Li MH; Yao YG
    EBioMedicine; 2022 Jan; 75():103803. PubMed ID: 34979342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.
    Saeedi-Boroujeni A; Mahmoudian-Sani MR; Nashibi R; Houshmandfar S; Tahmaseby Gandomkari S; Khodadadi A
    Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):247-258. PubMed ID: 34015982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.
    Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR
    Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
    Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
    Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
    Lécuyer D; Nardacci R; Tannous D; Gutierrez-Mateyron E; Deva Nathan A; Subra F; Di Primio C; Quaranta P; Petit V; Richetta C; Mostefa-Kara A; Del Nonno F; Falasca L; Marlin R; Maisonnasse P; Delahousse J; Pascaud J; Deprez E; Naigeon M; Chaput N; Paci A; Saada V; Ghez D; Mariette X; Costa M; Pistello M; Allouch A; Delelis O; Piacentini M; Le Grand R; Perfettini JL
    Front Immunol; 2023; 14():1270081. PubMed ID: 37920468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
    Zhao N; Di B; Xu LL
    Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage.
    Ma J; Zhu F; Zhao M; Shao F; Yu D; Ma J; Zhang X; Li W; Qian Y; Zhang Y; Jiang D; Wang S; Xia P
    EMBO J; 2021 Sep; 40(18):e108249. PubMed ID: 34296442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
    van den Berg DF; Te Velde AA
    Front Immunol; 2020; 11():1580. PubMed ID: 32670297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of inflammasome NLRP3 in the pathophysiology of viral infections: A focus on SARS-CoV-2 infection].
    Chemarin M; Dufies O; Mazet A; Mellan E; Coudereau R; Py BF; Boyer L; Venet F
    Med Sci (Paris); 2022; 38(6-7):545-552. PubMed ID: 35766852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19.
    López-Reyes A; Martinez-Armenta C; Espinosa-Velázquez R; Vázquez-Cárdenas P; Cruz-Ramos M; Palacios-Gonzalez B; Gomez-Quiroz LE; Martínez-Nava GA
    Front Immunol; 2020; 11():570251. PubMed ID: 33193349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.
    Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG
    Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
    Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
    Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of NLRP3 inflammasome in COVID-19 and periodontitis: Possible protective effect of melatonin.
    Şehirli AÖ; Aksoy U; Koca-Ünsal RB; Sayıner S
    Med Hypotheses; 2021 Jun; 151():110588. PubMed ID: 33848919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention.
    Zhang J; Ma X; Liu F; Zhang D; Ling J; Zhu Z; Chen Y; Yang P; Yang Y; Liu X; Zhang J; Liu J; Yu P
    Front Immunol; 2023; 14():1203389. PubMed ID: 37868953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells.
    Sur S; Steele R; Isbell TS; Ray R; Ray RB
    mBio; 2022 Jun; 13(3):e0095122. PubMed ID: 35587188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity.
    Amin S; Aktar S; Rahman MM; Chowdhury MMH
    Microbes Infect; 2022 Feb; 24(1):104913. PubMed ID: 34838941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats.
    Nagaraja S; Jain D; Kesavardhana S
    J Leukoc Biol; 2022 Feb; 111(2):497-508. PubMed ID: 34057760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases.
    Cama VF; Marín-Prida J; Acosta-Rivero N; Acosta EF; Díaz LO; Casadesús AV; Fernández-Marrero B; Gilva-Rodríguez N; Cremata-García D; Cervantes-Llanos M; Piniella-Matamoros B; Sánchez D; Del Rosario-Cruz L; Borrajero I; Díaz A; González Y; Pentón-Arias E; Montero-González T; Guillen-Nieto G; Pentón-Rol G
    J Neuroimmunol; 2021 Dec; 361():577728. PubMed ID: 34619427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Nexus of NLRP3 Inflammasomes and COVID-19 Pathogenesis: Unraveling Molecular Triggers and Therapeutic Strategies.
    He Q; Hu D; Zheng F; Chen W; Hu K; Liu J; Yao C; Li H; Wei Y
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.